Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) were up 4.8% during trading on Wednesday . The stock traded as high as $2.83 and last traded at $2.83. Approximately 3,101 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 16,025 shares. The stock had previously closed at $2.70.
Analyst Ratings Changes
Separately, Raymond James upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, May 22nd.
Read Our Latest Stock Analysis on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Stock Performance
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.17) EPS for the quarter.
Institutional Trading of Eupraxia Pharmaceuticals
A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $34,000.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Featured Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How Much Can You Make in Stocks in One Month?
- Stock Analyst Ratings and Canadian Analyst Ratings
- This Is the Top Large-Cap Stock Insiders Are Buying
- Do ETFs Pay Dividends? What You Need to Know
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.